Capricor Therapeutics, Inc.

Capricor Therapeutics Inc. is a biotechnology company focused on developing transformative cell and exosome-based therapeutics for the treatment and prevention of a variety of diseases. Primarily, the company harnesses the potential of its proprietary cardiosphere-derived cell (CDC) technology, which aims to address the unmet medical needs in cardiac and skeletal muscle conditions. Capricor is also pioneering in the exploration of engineered exosomes, tiny vesicles that can deliver therapeutic payloads to target cells effectively and safely. These endeavors position Capricor at the forefront of biotherapeutics innovation, with particular impacts on sectors such as regenerative medicine and precision medicine. Established as a leader in both cardiac and muscle disease treatments, the company's research and clinical trials play a crucial role in advancing potential therapeutic solutions. By collaborating with industries and research institutions, Capricor Therapeutics continues to contribute significantly to the biopharmaceutical landscape, with a promising portfolio that could redefine treatment paradigms in related medical fields.